Treatments directed against TLR4 signaling down-stream pro-inflammatory cytokines (e.g., TNF-α, IL-6 and IL-1β) are partially effective in SLE disease [64]–[67]. This evidence concerns the gene IL1B and systemic lupus erythematosus.